Talazoparib

• UNSPSC Description:

  Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity[1].

• Target Antigen:

  PARP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/BMN-673.html

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C1NN=C2C3=C1C=C(F)C=C3N[C@H](C4=CC=C(F)C=C4)[C@H]2C5=NC=NN5C

• Molecular Weight:

  380.35

• References & Citations:

  [1]Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57.|[2]Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19(18):5003-15.ACS Appl Mater Interfaces. 2019 Apr 3;11(13):12342-12356. |Adv Sci (Weinh). 2024 Jul 8:e2400140.|Adv Sci (Weinh). 2024 Mar 14:e2307940.|Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.|Am J Cancer Res. 2024 Jan 15;14(1):378-389.|Bioeng Transl Med. 2019 Jun 14;4(2):e10131. |Bioinformatics. 2022 Jul 26;btac533.|Biomed Res Int. 2023 Feb 6.|bioRxiv. 2023 Apr 17.|bioRxiv. 2023 Jun 22.|bioRxiv. 2023 Jun 28.|bioRxiv. 2024 Jul 10:2024.07.09.602803.|bioRxiv. 2024 Nov 26:2024.11.21.624591.|bioRxiv. April 22, 2021.|BMC Cancer. 2022 Mar 23;22(1):312.|Br J Cancer. 2024 May 28.|Cancer Cell Int. 2023 Jun 27;23(1):128.|Cancer Cell. 2020 Dec 14;38(6):844-856.e7.|Cancer Discov. 2017 Sep;7(9):984-998.|Cancer Discov. 2022 May 12;candisc.1181.2021.|Cancer Lett. 2021 Jan 22;S0304-3835(21)00024-0.|Cancer Lett. 2021 Mar 1;500:208-219.|Cancer Lett. 2022 Aug 1;215851.|Cancer Res. 2021 Jun 14.|Cancer Res. 2023 Sep 11.|Cell Biosci. 2024 Feb 6;14(1):20.|Cell Rep. 2023 Oct 16;42(10):113256.|Cell Rep. 2024 Jul 18;43(8):114522.|Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. |Data Brief. 22 September 2021, 107394.|Département de Pharmacologie et Physiologie, Faculté de Médecine. 2020 Jun.|Drug Des Devel Ther. 2020 Feb 25;14:783-793.|EBioMedicine. 2018 Dec;38:47-56. |EBioMedicine. 2020 Sep;59:102923.|Front Oncol. 2021 Jul 9;11:681441.|Genes (Basel). 2023 Jun 20, 14(6), 1295.|Int J Cancer. 2024 Apr 15.|Int J Mol Sci. 2022, 23(22), 14338|Int J Mol Sci. 2020 Feb 11;21(4):1185.|Integr Biol (Camb). 2019 Apr 1;11(4):130-141.|Invest New Drugs. 2021 Mar 12.|J Clin Invest. 2021 Jun 1;131(11):146256.|J Med Chem. 2023 Aug 21.|J Pers Med. 2023 Aug 27, 13(9), 1315.|Methods Mol Biol. 2018;1711:351-398.|Mol Cell. 2017 May 18;66(4):503-516.e5. |Nat Cancer. 2022 Oct;3(10):1211-1227.|Nat Commun. 2023 Dec 9;14(1):8161.|Nat Commun. 2019 Jun 11;10(1):2556. |Nat Genet. 2022 Dec;54(12):1983-1993.|Neoplasia. 2019 Jul 27;21(9):863-871.|Oncogene. 2017 Aug 17;36(33):4682-4691.|Oncogene. 2021 Sep 10.|Oncol Rep. 2019 Nov;42(5):2097-2107.|Oxid Med Cell Longev. 14 Jul 2022.|Patent. US20180263995A1.|Patent. US20180362972A1.|Patent. US20200078369A1|Patent. US20200129476A1|Patent. US20210030680A1.|Patent. US20220054606A1.|PLoS One. 2024 Apr 16;19(4):e0302130.|Radiother Oncol. 2021 Jan 29;157:175-181.|Research Square Preprint. 2024 Feb 2.|Research Square Print. January 4th, 2023.|Sci Adv. 2022 Feb 18;8(7):eabl9794.|Sci Rep. 2023 Feb 27;13(1):3334.|Theranostics. 2020 Jul 25;10(21):9477-9494. |University of London. 2021 Sep.|University of Pittsburgh. 2024.|DNA Repair (Amst). 2019 Jan;73:64-70.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  1207456-01-6